
C Gatran 110mg Tablet
Marketer
Cucard Pharma
Salt Composition
Dabigatran Etexilate (110mg)
Overview C Gatran 110mg Tablet
This anticoagulant medication, C Gatran 110mg Tablet, thins the blood, preventing and treating blood clots. Its use reduces stroke and heart attack risk by inhibiting clot formation in leg, lung, brain, and heart veins. Frequently prescribed for patients with atrial fibrillation to prevent clot formation, it also mitigates clotting risks post-knee or hip replacement. While it can be taken with or without food, consistent daily timing is recommended. Long-term use, potentially lifelong, may be necessary; discontinuation or dosage changes require physician approval to avoid increased stroke, heart attack, or thrombosis risk. Lifestyle modifications—such as avoiding smoking, healthy eating, regular exercise, and weight management—further minimize clotting risk. Common side effects include gastrointestinal upset and increased bleeding (e.g., nosebleeds, bruising). Report any adverse effects immediately. Other potential side effects include headaches, convulsions, allergic responses, visual disturbances, and fatigue. Contraindicated in patients with severe hepatic or renal impairment, active bleeding, or concurrent use of other anticoagulants. Breastfeeding is not advised during treatment. Unlike some anticoagulants, routine PT-INR monitoring isn't needed.
Primary Ingredients of C Gatran 110mg Tablet
There is no text provided to rephrase.
Uses of C Gatran 110mg Tablet
Preventing and managing blood clot formation
Major Benefits of C Gatran 110mg Tablet:
Administer this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment schedule. The tablet should be swallowed whole; avoid chewing, crushing, or fracturing it. C Gatran 110mg Tablets can be ingested with or without food; however, consistent timing is recommended.
Common Side effects of C Gatran 110mg Tablet:
- Nausea
- Anemia (low number of red blood cells)
- Gastrointestinal bleeding
- Dyspepsia
- Diarrhea
- Abdominal pain
- Nosebleeds
- Skin bleeding
How to use C Gatran 110mg Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. C Gatran 110mg Tablets can be administered with or without food, although consistent timing is recommended.
How C Gatran 110mg Tablet works:
Xarelto 110mg tablets are a new type of blood thinner, inhibiting clot development within the circulatory system.
SAFETY ADVICE
AlcoholUNSAFE
Combining C Gatran 110mg Tablets with alcohol is inadvisable.
PregnancyCONSULT YOUR DOCTOR
The use of C Gatran 110mg tablets during pregnancy may pose risks. While human research is scarce, animal studies indicate potential harm to the fetus. A physician will assess the potential benefits against any risks prior to prescribing. Physician consultation is advised.
Breast feedingCONSULT YOUR DOCTOR
Administration of C Gatran 110mg tablets while breastfeeding is likely inadvisable. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.
DrivingSAFE
Driving ability is typically unaffected by C Gatran 110mg Tablets.
KidneyCAUTION
Patients with severe kidney impairment should exercise caution when using C Gatran 110mg tablets, as dose modification may be necessary. Consult a physician before use. C Gatran 110mg tablets are not advised for individuals with severe kidney disease.
LiverCAUTION
Patients with liver impairment should use C Gatran 110mg Tablets cautiously; dosage modification may be necessary. Physician consultation is advised.
What if you forget to take C Gatran 110mg Tablet :
Should you forget a dose of your C Gatran 110mg Tablet, administer it as promptly as possible that same day. However, omit the missed dose if taking it within 6 hours of your next scheduled dose is not feasible. Avoid doubling the dose to compensate for a missed one.
Facts to Know About C Gatran 110mg Tablet
| Label | Value |
|---|---|
| Chemical Classification | Benzimidazole-based compound |
| Developing Habits | No. |
| Type of Therapy | Heart |
| Actions | Oral direct thrombin inhibitor |
